Ideas – Page 120

March 3, 2019

Published by admin_auro at March 3, 2019

Categories

Ribonucleic acid-based therapy for inflammation and arthritis: LncRNA ZFAS1 (zinc finger antisense (ZFAS)1 increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 3/March/2018, 9.13 am

Introduction: What they say A study from Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany shows that […]

March 3, 2019

Published by admin_auro at March 3, 2019

Categories

Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA CCAT1 inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 3/March/2019, 8.50 am

Introduction: What they say A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and […]

March 3, 2019

Published by admin_auro at March 3, 2019

Categories

Combinatorial therapy for attenuating prostate cancer bone metastasis: A pharmaceutical mixture encompassing Simvastatin and Navitoclax (SAN) inhibits the expression of Monoamine oxidase A (MAOA), inhibits Shh-IL6-RANKL signaling network, suppresses tumor-stromal interactions, reduces prostate cancer metastasis and prolongs survival via upregulation of its target gene, 3/March/2019, 8.33 am

Introduction: What they say: A study from the Uro-Oncology Research Program, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA shows that “MAOA-Dependent Activation of […]

March 3, 2019

Published by admin_auro at March 3, 2019

Categories

Ribonucleic acid-based therapy for inflammation and arthritis: LncRNA HOTAIRM1-1 (HOX antisense intergenic RNA myeloid 1 variant 1) increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 3/March/2018, 6.41 am

Introduction: What they say A study from Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany shows that […]